New Analysis Suggests that Jardiance Could Add Years to Life Expectancy of Adults With Type 2 Diabetes and Cardiovascular Disease

October 10, 2018
  • Empagliflozin was estimated to extend life expectancy by 1 to 4.5 years on average
  • In Sept of 2018 it was announced that the class of drugs that includes empagliflozin was associated with increased risk of necrotizing fasciitis of the perineum


on 10/10/18, the journal Circulation published novel results based on data from the landmark EMPA-REG OUTCOME  trial, which suggest that treatment with empagliflozin positively impacts life expectancy in adults with type 2 diabetes and established cardiovascular disease. Using actuarial methods*, and assuming that the demonstrated beneficial effects of empagliflozin remain consistent with long-term use, empagliflozin was estimated to extend life expectancy by 1 to 4.5 years on average, depending on age, when compared with placebo.This analysis suggests that treatment with empagliflozin could add years of life.

In an analysis of data from 7,020 patients included in the EMPA-REG OUTCOME trial, estimated life expectancy increased across all ages when adults were treated with empagliflozin as compared to those treated with placebo. Specifically, estimated mean survival in people aged 45 years was 32.1 years with empagliflozin versus 27.6 years with placebo, resulting in a mean survival difference of 4.5 years. In people aged 50, 60, 70 and 80 years old, the mean survival difference with empagliflozin compared to placebo was an additional 3.1 years, 2.5 years, 2 years and 1 year, respectively.


The primary EMPA-REG OUTCOME trial results, published in the New England Journal of Medicine in September 2015, demonstrated a 38 percent relative risk reduction in cardiovascular death and a 32 percent relative risk reduction in all-cause mortality with empagliflozin in people with type 2 diabetes and established cardiovascular disease, compared with placebo, over a period of 3.1 years. Modelling based on the EMPA-REG OUTCOME trial data was used to quantify the potential benefit of empagliflozin on residual life span.

In September of 2018 it was announced that empagliflozin along with other drugs in the class - canagliflozin,  dapagliflozin, and ertugliflozin were associated with increased risk of necrotizing fasciitis of the perineum , also known as Fournier gangrene. The FDA issued a warning about the increased risk.



CP Wire

Submit an article to cafepharma's CP Wire. Click here to find out more.

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.